TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01121354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 2g for Injection USP and Dextrose Injection USP
Description: Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1.5g
Description: Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
Study: NCT02957227

Intervention type: DEVICE
Intervention: No intervention is part of this study but patients use an EEG device during observational data collection.

Intervention type: DEVICE
Intervention: No intervention is part of this study but patients use an EEG device during observational data collection.
Study: NCT01743703

Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic whole body MRI
Description: diagnostic whole body MRI, both STIR and diffusion weighted
Study: NCT03630510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Description: The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
Study: NCT01688401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan hydrochloride
Description: Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks.
Study: NCT00618566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WPD and Depression Treatment Group
Description: Intervention selected will depend on Phase I data analysis.
Study: NCT01152385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet administered twice daily during 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet administered twice daily during 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet administered twice daily during 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered twice daily during 4 months
Study: NCT05450120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Rehabilitation
Description: Functional rehabilitation protocol
Study: NCT05450120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation
Description: Functional rehabilitation protocol
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight
Description: Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study: NCT05450120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular electrical stimulation protocol
Study: NCT02610023

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
Study: NCT02149797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four port laparoscopic cholecystectomy
Description: Classical four port laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILC-Pick'n roll-Beginning (group I)
Description: SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILC-Pick'n roll-Experienced (group II)
Description: Similar technique of SILC-Pick'n roll-Beginning (group I) was used
Study: NCT03177070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
Study: NCT02758080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching on the basis of molecular analysis

Intervention type: OTHER
Group type: OTHER
Intervention: Matching on the basis of physician's choice
Study: NCT01183182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: Three different groups of patients defined per lesion size
Study: NCT04117087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS peptide vaccine
Description: 1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS peptide vaccine
Description: 1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV
Study: NCT02610023

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Intervention: Spectroscopy
Description: Undergo resonance Raman spectroscopy
Study: NCT04806568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of daily activity
Description: Monitoring of daily activity via Fitbit Charge 4 smartwatch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of daily activity
Description: Monitoring of daily activity via Fitbit Charge 4 smartwatch.
Study: NCT04117087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV
Study: NCT01362530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Description: On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant powder for suspension (PFS)
Description: On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Day 1: Administered according to product label for pediatric usage or local standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Day 1: Administered according to product label for pediatric usage or local standard of care
Study: NCT03910959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Description: Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Parallelled conventional therapy sessions (treatment as usual)
Study: NCT04098601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Coach Intervention
Description: Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
Study: NCT01385696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair® (Almirall S.A.)
Description: Inhaler with only placebo, once daily, 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair® (Almirall S.A.)
Description: Inhaler with only placebo, once daily, 14 days
Study: NCT01362530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant 125 mg
Description: On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant 80 mg
Description: On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant PFS
Description: On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emetogenic chemotherapy
Description: Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emetogenic chemotherapy
Description: Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used.
Study: NCT04314180

Intervention type: DEVICE
Intervention: Taking slit-lamp images
Description: The participant only needs to take several slit-lamp images as usual.
Study: NCT01385696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler® (Boehringer Ingelheim's)
Description: Inhaler with only placebo, once daily, 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler® (Boehringer Ingelheim's)
Description: Inhaler with only placebo, once daily, 14 days
Study: NCT04154982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl cysteine
Description: 1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
Study: NCT00178412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Project for Hospitalized Elders & Family Caregivers
Description: Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center.
Study: NCT01956643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: gum chewing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Routine care during NPO
Study: NCT00932503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl plus
Description: triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
Study: NCT03390231

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
Study: NCT05738512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Flap Coblation Turbinoplasty
Description: Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
Study: NCT01366014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study: NCT05738512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucous Resection
Description: Submucous Resection
Study: NCT04792996

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. case - control design.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. case - control design.
Study: NCT03533790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP-Ru
Description: * Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone
Study: NCT01366014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT03976141

Intervention type: DIAGNOSTIC_TEST
Intervention: mri
Description: knee mri
Study: NCT02217982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Butter
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight
Description: Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight
Description: Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study: NCT01204112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib (CP-690,550) plus Rifampin
Description: Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
Study: NCT01495546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early loading
Description: Patients stepping down immediately after THA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late loading
Description: Patients stepping down after three weeks of HTA
Study: NCT01133639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus standard of care
Study: NCT03809572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: See Arm description
Study: NCT01448551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Mobile Messages to Enhance Weight Loss for Teens
Description: For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
Study: NCT00693212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Dosing was flexible and dependent on clinical judgement, AEs and treatment response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosing is identical to the MPH arm except that the pills will contain no active medication.
Study: NCT02602873

Intervention type: OTHER
Intervention: therapeutic drug monitoring
Description: with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.

Intervention type: OTHER
Intervention: therapeutic drug monitoring
Description: with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
Study: NCT02044146

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor, Prasugrel, Clopidogrel
Study: NCT03412630

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo computed tomography perfusion imaging
Study: NCT02261480

Intervention type: OTHER
Intervention: Blood draw
Description: When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.

Intervention type: OTHER
Intervention: Blood draw
Description: When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.

Intervention type: OTHER
Intervention: Blood draw
Description: When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.

Intervention type: OTHER
Intervention: Nasopharyngeal wash
Description: Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
Study: NCT02044146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor, Prasugrel, Clopidogrel